What to watch with CYP2C19 and Langlebigkeit?

CYP2C19 is a cytochrome P450 enzyme primarily involved in metabolizing drugs such as clopidogrel, proton pump inhibitors (e.g., omeprazole), and certain antidepressants. Direct evidence linking CYP2C19 variants to longevity is weak. However, polymorphisms (*2, *3, *17) can alter drug efficacy and safety, which may indirectly affect healthspan. For example, poor metabolizers have higher clopidogrel active metabolite levels (increased bleeding risk), while ultrarapid metabolizers may experience reduced antiplatelet effect, potentially impacting cardiovascular outcomes. Since cardiovascular disease is a major determinant of lifespan, CYP2C19 status could play a role – but the effect is indirect and context-dependent (medication use, liver function, co-medications). Current evidence is moderate and not specifically designed for longevity endpoints. Consumer genetic tests often report CYP2C19, but claims about direct longevity benefits are overblown. A more prudent approach: use CYP2C19 information to guide pharmacotherapy when relevant, not as a standalone longevity marker.